MedTrace Logo

Real-world Evidence Study on Cystistat

NCT05544695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2026-01-09

Study results available
· View outcomes & findings →

Summary

This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime. Cystistat is supplied as a 50 mL solution containing 40 mg of sodium hyaluronate. It is indicated for the temporary replacement of the GAG layer in the bladder.

Conditions

  • Interstitial Cystitis and Bladder Pain Syndrome

Interventions

DEVICE

intravesical sodium hyaluronate (Cystistat®)

Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-21
Primary Completion
2024-07-29
Completion
2024-07-29

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544695 on ClinicalTrials.gov